Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.47 |
| ▸ | SLC6A2 | P23975 | 1/20 | 0.47 |
| ▸ | ESR1 | P03372 | 5/20 | 0.46 |
| ▸ | ESR2 | Q92731 | 5/20 | 0.46 |
| ▸ | ACE | P12821 | 1/20 | 0.43 |
| ▸ | CTSB | P07858 | 2/20 | 0.41 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
| ▸ | CRHBP | P24387 | 1/20 | 0.40 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.40 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.40 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.40 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.40 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.40 |
| ▸ | SLC7A5 | Q01650 | 1/20 | 0.40 |
| ▸ | MIF | P14174 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12703579 | 0.83 | ACE (0.43) | TAAR1SLC6A2ESR1ESR2ACE | |
| SCHEMBL4541734 | 0.82 | TAAR1 (0.46) | TAAR1SLC6A2ESR1ESR2CTSB | |
| SCHEMBL9630785 | 0.82 | TAAR1 (0.46) | TAAR1SLC6A2ESR1ESR2CTSB | |
| SCHEMBL12873856 | 0.82 | ACE (0.56) | TAAR1ACECTSB | |
| SCHEMBL10044549 | 0.82 | ACE (0.56) | TAAR1ACECTSB | |
| SCHEMBL12154596 | 0.82 | TAAR1 (0.46) | TAAR1SLC6A2ESR1ESR2CTSB | |
| SCHEMBL18079679 | 0.80 | SLC7A5 (0.43) | TAAR1SLC6A2ESR1ESR2ACE | |
| SCHEMBL17135385 | 0.80 | SLC7A5 (0.43) | TAAR1SLC6A2ESR1ESR2ACE | |
| SCHEMBL23845056 | 0.79 | CYP3A4 (0.40) | TAAR1ACECTSBMAPTCYP1A2 | |
| SCHEMBL8593961 | 0.79 | SLC7A5 (0.46) | TAAR1SLC6A2ESR1ESR2ACE |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200190178-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | H. LUNDBECK A/S (DK) | 2020-06-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200190178-A1 | ANTIBODIES SPECIFIC FOR HYPERPHOSPHORYLATED TAU AND METHODS OF USE THEREOF | MAPT, PSEN2, PSEN1 | TAAR1 3938/4885SLC6A2 1701/4885ESR1 4716/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.